Why the study?
Does the PRV ΔTK&gE-AH02 vaccine candidate provide safe and effective protection against virulent pseudorabies virus challenge in piglets?
Does the PRV ΔTK&gE-AH02 vaccine candidate provide safe and effective protection against virulent pseudorabies virus challenge in piglets?
The PRV ΔTK&gE-AH02 mutant is a safe and highly immunogenic vaccine candidate that provides complete clinical protection and stops virus shedding against the emerging PRV variant in pigs.
No takes yet. Share an insight, caveat, or question.
TK/gE-deficient PRV mutant offers a balanced vaccine candidate; leaves open in vivo safety and efficacy trials in pigs.
Wang et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: